missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD52 Monoclonal Antibody (CF1D12), PerCP-eFluor™ 710, eBioscience™, Invitrogen™
Mouse Monoclonal Antibody
Marque: Invitrogen™ 46-0529-42
Les retours ne sont pas autorisés pour ce produit.
Afficher la politique du retour.
Description
This CF1D12 monoclonal antibody reacts with human CD52, a cell surface glycoprotein expressed in the immune and reproductive systems. CF1D12 is thought to recognize the carbohydrate region of CD52, not the protein core of the molecule. Tissue-specific mod
CD52, also known as CAMPATH-1 antigen, is a glycoprotein that is expressed on the surface of various immune cells, including T and B lymphocytes, natural killer cells, and monocytes. It is involved in the regulation of immune responses and is being studied as a potential therapeutic target in various diseases, including multiple sclerosis, chronic lymphocytic leukemia, and autoimmune disorders. CD52 is the target of alemtuzumab, a monoclonal antibody that is used to treat these conditions by depleting immune cells that express CD52.
Spécification
| CD52 | |
| Monoclonal | |
| 5 μL/Test | |
| PBS with BSA and 0.09% sodium azide; pH 7.2 | |
| P31358 | |
| CD52 | |
| Human CD52. | |
| 100 Tests | |
| Primary | |
| Human | |
| Antibody | |
| IgG3 κ |
| Flow Cytometry | |
| CF1D12 | |
| PerCP-eFluor 710 | |
| CD52 | |
| AI463198; B7; B7-Ag; cambridge pathology 1 antigen; CAMPATH-1; CAMPATH-1 antigen; Cd52; CD52 antigen; CD52 antigen (CAMPATH-1 antigen); CD52 molecule; CDW52; CDW52 antigen (CAMPATH-1 antigen); CLS1; Epididymal secretory protein E5; epididymis secretory sperm binding protein Li 171mP; he5; HEL-S-171mP; human epididymis-specific protein 5; Lymphocyte differentiation antigen B7; Mb7 | |
| Mouse | |
| Affinity chromatography | |
| RUO | |
| 1043 | |
| 4°C, store in dark, DO NOT FREEZE! | |
| Liquid |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu